CLASS ACTION UPDATE for MDP, MYGN and TEUM: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders

NEW YORK, NY / ACCESSWIRE / November 5, 2019 / Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies. To determine your eligibility and get free access to our shareholder support tools that provide you with case updates, automated loss calculations and claims recovery assistance, please contact the firm via the links below. There will be no cost or obligation to you.

Meredith Corporation (NYSE:MDP)

Lawsuit on behalf of: investors who purchased January 31, 2018 - September 5, 2019
Lead Plaintiff Deadline : November 5, 2019
TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/meredith-corporation-loss-form?prid=4180&wire=1

According to the filed complaint, during the class period, Meredith Corporation made materially false and/or misleading statements and/or failed to disclose that: (1) the Time, Inc. acquisition was not as profitable as the Company had claimed; (2) the Company would incur additional costs for strategic investments to improve the Time business; (3) as a result, the Company's earnings would be materially and adversely impacted; and (4) as a result of the foregoing, Defendants' positive statements about the Company's business, operations, and prospects, were materially misleading and/or lacked a reasonable basis.

Myriad Genetics, Inc. (NASDAQ:MYGN)

Lawsuit on behalf of: investors who purchased September 2, 2016 - August 13, 2019
Lead Plaintiff Deadline : November 26, 2019
TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/myriad-genetics-inc-loss-form?prid=4180&wire=1

According to the filed complaint, during the class period, Myriad Genetics, Inc. made materially false and/or misleading statements and/or failed to disclose that: (i) Myriad's product, GeneSight, lacked evidence or information sufficient to support the tests in their current form, including their purported benefits; (ii) the U.S. Food and Drug Administration ("FDA") had requested changes to GeneSight and questioned the validity of the test's purported benefits; (iii) Myriad had been in ongoing discussions with the FDA regarding the FDA's requested changes to GeneSight; (iv) Myriad's acquisition of Counsyl-and thereby, Foresight-caused the Company to incur the risk of suffering from lower reimbursement for its expanded carrier screening tests, which had the potential to, and actually did, materialize into a material negative impact on the Company's revenue; and (v) as a result, the Company's public statements were materially false and misleading at all relevant times.

Pareteum Corporation (NASDAQ:TEUM)

Lawsuit on behalf of: investors who purchased December 14, 2017 - October 21, 2019
Lead Plaintiff Deadline : December 23, 2019
TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/pareteum-corporation-loss-form?prid=4180&wire=1

According to the filed complaint, during the class period, Pareteum Corporation made materially false and/or misleading statements and/or failed to disclose that: (a) it was not true that the Company's purported success was the result of hyper-demand for Pareteum's unique products or exceptional service, or the Company's competent management; but, in fact, Defendants had propped up the Company's results by manipulating Pareteum's accounting for revenues, income, and the important Backlog metric; (b) Defendants had materially overstated the Company's profitability by failing to properly account for the Company's results of operations and by artificially inflating the Company's financial results; (c) it was not true that Pareteum contained even the most minimally adequate systems of internal operational or financial controls necessary to assure that Pareteum's reported financial statements were true, accurate, and/or reliable; (d) as a result, it also was not true that the Company's financial statements and reports were prepared in accordance with GAAP and SEC rules; and (e) as a result of the aforementioned adverse conditions, Defendants lacked any reasonable basis to claim that Pareteum was operating according to plan, or that Pareteum could achieve the guidance sponsored and/or endorsed by Defendants.

You have until the lead plaintiff deadlines to request that the court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.

Levi & Korsinsky is a national firm with offices in New York, California, Connecticut, and Washington D.C. The firm's attorneys have extensive expertise and experience representing investors in securities litigation and have recovered hundreds of millions of dollars for aggrieved shareholders. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:
Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
55 Broadway, 10th Floor
New York, NY 10006
jlevi@levikorsinsky.com
Tel: (212) 363-7500
Fax: (212) 363-7171
www.zlk.com

SOURCE: Levi & Korsinsky, LLP



View source version on accesswire.com:
https://www.accesswire.com/565367/CLASS-ACTION-UPDATE-for-MDP-MYGN-and-TEUM-Levi-Korsinsky-LLP-Reminds-Investors-of-Class-Actions-on-Behalf-of-Shareholders

Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.